Search Result

Results for "

Urolithin A

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (3) AMPK (7) Apoptosis (6) Autophagy (6) Bacterial (2) Biochemical Assay Reagents (1) Calcium Channel (2) DNA/RNA Synthesis (3) Drug Metabolite (3) EGFR (1) Endogenous Metabolite (8) Ephrin Receptor (2) ERK (2) Influenza Virus (1) Isotope-Labeled Compounds (1) JNK (2) NF-κB (2) Organoid (3) p38 MAPK (1) PPAR (2) Reactive Oxygen Species (ROS) (6) Reference Standards (4) TGF-β Receptor (3) Tyrosinase (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (4) Metabolic Disease (5) Neurological Disease (1)

By Targets:

Akt (3)

AMPK (7)

Apoptosis (6)

Autophagy (6)

Bacterial (2)

Biochemical Assay Reagents (1)

Calcium Channel (2)

DNA/RNA Synthesis (3)

Drug Metabolite (3)

EGFR (1)

Endogenous Metabolite (8)

Ephrin Receptor (2)

ERK (2)

Influenza Virus (1)

Isotope-Labeled Compounds (1)

JNK (2)

NF-κB (2)

Organoid (3)

p38 MAPK (1)

PPAR (2)

Reactive Oxygen Species (ROS) (6)

Reference Standards (4)

TGF-β Receptor (3)

Tyrosinase (1)

By Research Areas:

Cancer (9)

Cardiovascular Disease (1)

Infection (1)

Inflammation/Immunology (4)

Metabolic Disease (5)

Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100599

Urolithin A Maximum Cited Publications 46 Publications Verification	Drug Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis Autophagy Apoptosis Endogenous Metabolite	Cancer
Urolithin A, a gut-microbial metabolite of ellagic acid, exerts anti-inflammatory, antiproliferative, and antioxidant properties. Urolithin A induces autophagy and apoptosis, suppresses cell cycle progression, and inhibits DNA synthesis .

HY-13418A

Dorsomorphin Maximum Cited Publications 754 Publications Verification Compound C; BML-275	Organoid AMPK TGF-β Receptor Autophagy	Cancer
Dorsomorphin (Compound C) is a selective and ATP-competitive AMPK inhibitor (K_i=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599) .

HY-13418

Dorsomorphin dihydrochloride Maximum Cited Publications 754 Publications Verification Compound C dihydrochloride; BML-275 dihydrochloride	Organoid AMPK TGF-β Receptor Autophagy	Cancer
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a K_i of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).

HY-126307

Urolithin B 5+ Cited Publications	NF-κB JNK ERK Akt AMPK Endogenous Metabolite	Inflammation/Immunology
Urolithin B is one of Ellagitannins' slow microbial products, and has anti-inflammatory and anti-inflammatory effects. Urolithin B suppresses NF-κB activity. Urolithin B suppresses JNK, ERK and Akt's oxidation, and increases AMPK's oxidation. Urolithin B is also a quantitative change factor for bone and skin quality .

HY-135897

Urolithin C 5 Publications Verification	Calcium Channel Reactive Oxygen Species (ROS) Apoptosis Endogenous Metabolite	Metabolic Disease
Urolithin C, a gut-microbial metabolite of Ellagic acid, is a glucose-dependent activator of insulin secretion. Urolithin C is a L-type Ca ²⁺ channel opener and enhances Ca ²⁺ influx. Urolithin C induces cell apoptosis through a mitochondria-mediated pathway and also stimulates reactive oxygen species (ROS) formation .

HY-N7922

Urolithin M5 1 Publications Verification Decarboxyellagic acid	Influenza Virus p38 MAPK EGFR Akt Reactive Oxygen Species (ROS) Apoptosis	Infection Neurological Disease
Urolithin M5 (Decarboxyellagic acid) is an orally active influenza virus neuraminidase inhibitor and neuroprotective agent, with IC₅₀ values of 174.8 μM (HK68), 191.5 μM (pdm09), 243.2 μM (WSN) and 257.1 μM (PR8) against four influenza virus neuraminidases, respectively. Urolithin M5 inhibits viral neuraminidase activity, thereby blocking influenza virus replication (including oseltamivir (HY-13317)-resistant strains), protecting infected mammals from death and improving pulmonary edema. Urolithin M5 forms a hydrogen-bond stabilized complex with IGF1R, and binds to MAPK14, AKT1, NFKB1 and EGFR. Urolithin M5 reduces reactive oxygen species production, inhibits neuronal apoptosis, restores mitochondrial transmembrane potential, and promotes neurite outgrowth of damaged neuronal cells. Urolithin M5 can be used in research related to influenza virus infection and Alzheimer's disease .

HY-N0445

2-Hydroxy-4-methoxybenzaldehyde	Tyrosinase Bacterial	Cancer
2-hydroxy-4-methoxybenzaldehyde is a potent tyrosinase inhibitor . 2-Hydroxy-4-methoxybenzaldehyde, an isomer of Vanillin, could be used to synthesis Urolithin M7

HY-133178

Urolithin D 3,4,8,9-Tetrahydroxy Urolithin	Ephrin Receptor PPAR AMPK	Metabolic Disease Inflammation/Immunology Cancer
Urolithin D (3,4,8,9-Tetrahydroxy urolithin) is a colonic metabolite of Ellagitannins and a competitive, reversible, and selective antagonist of the EphA receptor. Urolithin D inhibits EphA2-ephrin-A1 binding with an IC₅₀ of 0.9 μM. Urolithin D is also a potent antioxidant that scavenges free radicals and repairs oxidized DNA damage. Additionally, Urolithin D suppresses triglyceride accumulation and promotes fatty acid oxidation by activating the AMPK signaling pathway. Urolithin D can be used for research on tumors, metabolic, and inflammatory diseases .

HY-N7921

Urolithin M6	Bacterial	Others
Urolithin M6 is a polyhydroxy-rich metabolite with potential antioxidant activity. Urolithin M6 is produced by intestinal microbial metabolism and may act as an analog of tannic acid compounds. The production of Urolithin M6 in humans requires specific bacterial 3-dehydroxylase activity, which provides a new mechanism for its biotransformation. The metabolic profile of Urolithin M6 helps to stratify volunteers and further explore its potential role in health and disease .

HY-N8049

Urolithin M7	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Urolithin M7 is an orally active metabolite, which is generated through gut microbiota metabolism. Urolithin M7 inhibits oxidative stress and modulates inflammatory signaling pathways. Urolithin M7 is promising for research of gut microbiota metabolism and cardiovascular diseases .

HY-W746164

Urolithin E	Biochemical Assay Reagents	Others
Urolithin E is a biological molecule.

HY-100599R

Urolithin A (Standard)	Reference Standards Drug Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis Autophagy Apoptosis Endogenous Metabolite	Cancer
Atractylodin (Standard) is the analytical standard of Atractylodin. This product is intended for research and analytical applications. Atractylodin (Atractydin) is an orally active active ingredient obtained from the rhizome of Atractylodes lancea and A. chinensis. Atractylodin is a natural insecticide. Atractylodin has anti-inflammatory activity .

HY-100599S2

Urolithin A-13C6	Isotope-Labeled Compounds Drug Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis Autophagy Apoptosis Endogenous Metabolite	Cancer
Urolithin A- ¹³C₆ is the ¹³C-labeled Urolithin A (HY-100599). Urolithin A, a gut-microbial metabolite of ellagic acid, exerts anti-inflammatory, antiproliferative, and antioxidant properties. Urolithin A induces autophagy and apoptosis, suppresses cell cycle progression, and inhibits DNA synthesis .

HY-133178R

Urolithin D (Standard) 3,4,8,9-Tetrahydroxy Urolithin (Standard)	Reference Standards Ephrin Receptor PPAR AMPK	Metabolic Disease Inflammation/Immunology Cancer
Urolithin D (Standard) (3,4,8,9-Tetrahydroxy urolithin (Standard)) is the analytical standard of Urolithin D (HY-133178). This product is intended for research and analytical applications. Urolithin D (3,4,8,9-Tetrahydroxy urolithin) is a colonic metabolite of Ellagitannins and a competitive, reversible, and selective antagonist of the EphA receptor. Urolithin D inhibits EphA2-ephrin-A1 binding with an IC₅₀ of 0.9 μM. Urolithin D is also a potent antioxidant that scavenges free radicals and repairs oxidized DNA damage. Additionally, Urolithin D suppresses triglyceride accumulation and promotes fatty acid oxidation by activating the AMPK signaling pathway. Urolithin D can be used for research on tumors, metabolic, and inflammatory diseases .

HY-126307R

Urolithin B (Standard)	NF-κB JNK ERK Akt AMPK Endogenous Metabolite Reference Standards	Inflammation/Immunology
Urolithin B (Standard) is the analytical standard of Urolithin B. This product is intended for research and analytical applications. Urolithin B is one of Ellagitannins' slow microbial products, and has anti-inflammatory and anti-inflammatory effects. Urolithin B suppresses NF-κB activity. Urolithin B suppresses JNK, ERK and Akt's oxidation, and increases AMPK's oxidation. Urolithin B is also a quantitative change factor for bone and skin quality .

HY-135897R

Urolithin C (Standard)	Calcium Channel Reactive Oxygen Species (ROS) Apoptosis Endogenous Metabolite	Metabolic Disease
Urolithin C (Standard) is the analytical standard of Urolithin C. This product is intended for research and analytical applications. Urolithin C, a gut-microbial metabolite of Ellagic acid, is a glucose-dependent activator of insulin secretion. Urolithin C is a L-type Ca2+ channel opener and enhances Ca2+ influx. Urolithin C induces cell apoptosis through a mitochondria-mediated pathway and also stimulates reactive oxygen species (ROS) formation .

HY-13418R

Dorsomorphin dihydrochloride (Standard) Compound C dihydrochloride (Standard); BML-275 dihydrochloride (Standard)	Organoid AMPK TGF-β Receptor Autophagy Reference Standards	Cancer
Dorsomorphin (dihydrochloride) (Standard) is the analytical standard of Dorsomorphin (dihydrochloride). This product is intended for research and analytical applications. Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).

Cat. No.	Product Name	Category	Target	Chemical Structure